223 Longitudinal change in ATN biomarkers REFERENCES 1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):263–9. 2. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 018;14(4):535–62. 3. Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, et al. ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology. 2020;95(1):e46–58. 4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science (New York, NY). 2002;297(5580):353–6. 5. Tan MS, Ji X, Li JQ, Xu W, Wang HF, Tan CC, et al. Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia. Alzheimers Res Ther. 2020;12(1):55. 6. Ebenau JL, Verfaillie SCJ, van den Bosch KA, Timmers T, Wesselman LMP, van Leeuwenstijn M, et al. Grey zone amyloid burden affects memory function: the SCIENCe project. Eur J Nucl Med Mol Imaging. 2021;48(3):747–56. 7. Landau SM, Horng A, Jagust WJ. Memory decline accompanies subthreshold amyloid accumulation. Neurology. 2018;90(17):e1452–e60. 8. Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology. 2018;91(19):e1809– e21. 9. Elman JA, Panizzon MS, Gustavson DE, Franz CE, Sanderson-Cimino ME, Lyons MJ, et al. Amyloid-β positivity predicts cognitive decline but cognition predicts progression to amyloid-β positivity. Biol Psychiatry. 2020;87(9):819–28. 10. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):270–9. 11. Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, et al. Quantification of [(18)F]florbetapir: a test-retest tracer kinetic modelling study. J Cerebr Blood Flow Metab. 2019;39(11):2172–80. 12. Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, et al. Quantification of tau load using [(18)F]AV1451 PET. Mol Imaging Biol. 2017;19(6):963–71. 13. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam dementia cohort. J Alzheimer’s Dis. 2014;41(1):313–27. 14. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Threedimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224–47. 8
RkJQdWJsaXNoZXIy MjY0ODMw